Evaluation and Comparison of the Preventive Role of Nebivolol and Alpha- Tocopherol in Testosterone-Induced Benign Prostatic Hyperplasia in Rats

Malik Sikandar Mehmood; Akbar Waheed; Shabana Ali; Arooj Shahid; Uzma Naeem

doi:10.51253/pafmj.v74i2.11039

Authors

Malik Sikandar Mehmood Department of Pharmacology, Army Medical College Rawalpindi / National University of Medical Sciences (NUMS) Pakistan
Akbar Waheed Department of Pharmacology, Army Medical College Rawalpindi / National University of Medical Sciences (NUMS) Pakistan
Shabana Ali Department of Pharmacology, Army Medical College Rawalpindi / National University of Medical Sciences (NUMS) Pakistan
Arooj Shahid Department of Pharmacology, Army Medical College Rawalpindi / National University of Medical Sciences (NUMS) Pakistan
Uzma Naeem Department of Pathology, Army Medical College Rawalpindi / National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i2.11039

Keywords:

Alpha-tocopherol, Benign prostatic hyperplasia, Nebivolol

Abstract

Objective: To evaluate and compare the preventive role of Nebivolol and Alpha Tocopherol on testosterone-induced benign prostatic hyperplasia in rats.

Study Design: Laboratory-based experimental study

Place and Duration of Study: Department of Pharmacology and Pathology, Army Medical College, Rawalpindi, in collaboration with National Institute of Health (NIH), Islamabad Pakistan, from Dec 2021 to Jun 2022.

Methodology: One hundred fifty healthy male Sprague-Dawley rats were procured from the NIH, Islamabad. They were placed into five groups, each with 30 rats.

Results: Out of a total 150 sample of five groups, the mean prostatic index in Group-A, Group-B, Group-C, Group-D, and Group-E were 1.49±0.09, 2.35±0.48, 1.87±0.11, 1.72±0.04 and 1.68±0.08 respectively (p-value< 0.001). Mean Prostate Specific Antigen in Group-A, Group-B, Group-C, Group-D and Group-E was 0.19±0.02, 0.23±0.01, 0.18±0.02, 0.18±0.02 and 0.16±0.02 respectively (p-value< 0.001). On gross examination, in Group-A, all (100%) prostate samples were normal-sized. In Group-B, all (100%) prostate samples were enlarged. In Group-C, 53.3% were mild, and 47.7% of samples were moderately enlarged. In Group-D, 73.3% of samples were mildly enlarged, and 26.7% were moderately enlarged. In Group E, 26.7% of samples were normal, and 73.3% were mildly enlarged (p-value< 0.001).

Conclusion: Prostatic index is markedly declined following treatment with the combination of Nebivolol and Alpha-Tocopherol. There is also a declining trend in Prostate Specific Antigen following treatment with a combination of Nebivolol and Alpha-Tocopherol.

Downloads

Download data is not yet available.

References

Robert G, De-La Taille A, Descazeaud A. Données épidémiologiques en rapport avec la prise en charge de l HBP [Epidemiology of benign prostatic hyperplasia]. Prog Urol 2018; 28(15): 803-812. https://doi.org/10.1016/j.purol.2018.08.005

Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int 2021; 127(6): 722-728. https://doi.org/10.1111/bju.15286

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019; 8(5): 529-539.

https://doi.org/10.21037/tau.2019.10.01

Yue L, Wang T, Ge Y, Ge M, Zhang C, Hou Q, et al. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. Prostate 2019; 79(3): 312-319. https://doi.org/10.1002/pros.23737

Miernik A, Gratzke C. Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int 2020; 117(49): 843-854.

https://doi.org/10.3238/arztebl.2020.0843

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019 8(5): 529-539. https://doi.org/10.21037/tau.2019.10.01

Sayani S, Muzammil M, Saleh K, Muqeet A, Zaidi F, Shaikh T. Addressing cost and time barriers in chronic disease management through telemedicine: an exploratory research in select low- and middle-income countries. Ther Adv Chronic Dis 2019; 10: 2040622319891587.

https://doi.org/10.1177/2040622319891587.

Özler S, Pazarci P. Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways. Anticancer Drugs 2022; 33(4): 384-388.

https://doi.org/10.1097/CAD.0000000000001271

AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic Properties of Highly Selective β-blockers with or without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovasc Drugs Ther 2022; 36(5): 959-971.

https://doi.org/10.1007/s10557-021-07205-y

Asay S, Graham A, Hollingsworth S, Barnes B, Oblad RV, Michaelis DJ, et al. γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells. Molecules 2020; 25(2): 398.

https://doi.org/10.3390/molecules25020398

King L, Christie D, Arora D, Anoopkumar-Dukie S. Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. Prostate Int 2020; 8(1): 34-40.

https://doi.org/10.1016/j.prnil.2019.10.004

Golchin-Rad K, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Derakhshandeh N, Abbaszadeh-Hasiri M, et al. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride. Top Companion Anim Med 2020; 38: 100405.

https://doi.org/10.1016/j.tcam.2020.100405

Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998 18; 90(6): 440-446. https://doi.org/10.1093/jnci/90.6.440

Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2021; 24(1) :49-57. https://doi.org/10.1038/s41391-020-00277-1

Cinislioglu AE, Demirdogen SO, Cinislioglu N, Altay MS, Sam E, Akkas F, et al. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys. Urology 2022; 159: 16-21.

https://doi.org/10.1016/j.urology.2021.09.016

Sabur V, Untan I, Tatlisen A. Role of PSA Kinetics in Hormone-refractory Prostate Cancer. J Coll Physicians Surg Pak 2021; 31(6): 673-678. https://doi.org/10.29271/jcpsp.2021.06.673

Al-Trad B, Al-Zoubi M, Qar J, Al-Batayneh K, Hussien E, Muhaidat R, et al. Inhibitory Effect of Thymoquinone on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. Phytother Res. 2017; 31(12): 1910-1915.

https://doi.org/10.1002/ptr.5936

Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. Onco Targets Ther 2015; 8: 985-990.

https://doi.org/10.2147/OTT.S78836

Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014; 65(3): 635-641.

https://doi.org/10.1016/j.eururo.2013.01.007

Gossell-Williams M, Lyttle K, Clarke T, Gardner M, Simon O. Supplementation with pumpkin seed oil improves plasma lipid profile and cardiovascular outcomes of female non-ovariectomized and ovariectomized Sprague-Dawley rats. Phytother Res 2008; 22(7): 873-877.

https://doi.org/10.1002/ptr.2381